HG-7-85-01 effect on apoptosis
Cell line . | Percentage . | HG-7-85-01, 0μM . | HG-7-85-01, 0.01μM . | HG-7-85-01, 0.1μM . | HG-7-85-01, 1μM . |
---|---|---|---|---|---|
32D-BCR-ABL | Viable | 96.5 | 94 | 47.1 | 4.6 |
Apoptotic | 3.3* | 5.8* | 52.3* | 95.3* | |
Necrotic | 0.2 | 0.2 | 0.6 | 0.1 | |
32D-BCR-ABL-T315I | Viable | 96.6 | 90.8 | 89.9 | 27.2 |
Apoptotic | 3.4* | 9* | 9.8* | 72.7* | |
Necrotic | 0 | 0.1 | 0.3 | 0 | |
Ba/F3-KIT-T670I | Viable | 96.8 | 97.7 | 96.9 | 91.6 |
Apoptotic | 3.2* | 2.3* | 3.1* | 8.4* | |
Necrotic | 0 | 0 | 0 | 0 | |
Ba/F3-PDGFRα-T674M | Viable | 92.2 | 91 | 34.7 | 13.2 |
Apoptotic | 7.8* | 9* | 65.2* | 86.8* | |
Necrotic | 0 | 0 | 0 | 0.1 | |
Ba/F3-PDGFRα-T674I | Viable | 87.3 | 61.9 | 15.2 | 5.8 |
Apoptotic | 12.8* | 38.1* | 84.7* | 94.1* | |
Necrotic | 0 | 0.1 | 0.2 | 0 |
Cell line . | Percentage . | HG-7-85-01, 0μM . | HG-7-85-01, 0.01μM . | HG-7-85-01, 0.1μM . | HG-7-85-01, 1μM . |
---|---|---|---|---|---|
32D-BCR-ABL | Viable | 96.5 | 94 | 47.1 | 4.6 |
Apoptotic | 3.3* | 5.8* | 52.3* | 95.3* | |
Necrotic | 0.2 | 0.2 | 0.6 | 0.1 | |
32D-BCR-ABL-T315I | Viable | 96.6 | 90.8 | 89.9 | 27.2 |
Apoptotic | 3.4* | 9* | 9.8* | 72.7* | |
Necrotic | 0 | 0.1 | 0.3 | 0 | |
Ba/F3-KIT-T670I | Viable | 96.8 | 97.7 | 96.9 | 91.6 |
Apoptotic | 3.2* | 2.3* | 3.1* | 8.4* | |
Necrotic | 0 | 0 | 0 | 0 | |
Ba/F3-PDGFRα-T674M | Viable | 92.2 | 91 | 34.7 | 13.2 |
Apoptotic | 7.8* | 9* | 65.2* | 86.8* | |
Necrotic | 0 | 0 | 0 | 0.1 | |
Ba/F3-PDGFRα-T674I | Viable | 87.3 | 61.9 | 15.2 | 5.8 |
Apoptotic | 12.8* | 38.1* | 84.7* | 94.1* | |
Necrotic | 0 | 0.1 | 0.2 | 0 |
Induction of apoptosis by HG-7-85-01 in BCR-ABL–, BCR-ABL-T315I–, KIT- T670I–, PDGFRα-T674M–, and PDGFRα-T674I–expressing cells after approximately 3 days of treatment.
Percentages of apoptotic cells for each cell line.